Big Mover FAQs
What is a Big Mover™ event? Big Mover™ events are upcoming high-impact biopharma catalyst events, usually clinical trial read-outs, that are expected to move a stock by at least 20% up or down. Big Mover™ events are typically a type of event with the highest chance of moving a stock (e.g. Phase 2, Phase 3, and PDUFA read-outs) for which stock options data indicates that a stock is likely to move up or down by at least 20%. If you are a BPIQ subscriber (Free 14-day trial from bpiq.com), See our February 2021 Big Mover analysis (HERE), for more detail about our methodology. What is the difference between a Big Mover event and a SUSPECTED Big Mover event? A Big Mover™ event is confirmed by options volatility data as an event that falls within a time frame in which options traders see a lot of possible price movement in the underlying stock. Big Mover events typically fall within 3 months from the time we do our analysis. A Suspected Big Mover event, is an event that is either too far out for us to call it a Big Mover (Future Suspected Big Mover), or is an event for which there is either no options volatility date on the underlying stock or the options volatility data is not above the cutoff we use a Big Mover event.
Are Big Mover™ events expected to drive an underlying stock price significantly higher? Big-Mover™ read outs can move an underlying stock higher OR LOWER. More specifically, Big-Mover™ events are upcoming high-impact biopharma catalyst events, for which a clear positive or negative result is expected to move a stock either up OR DOWN, respectively, by at least 20%. How can I assure that I have access to upcoming Big Mover™ analysis? Become a BPIQ Elite subscriber or an Amp subscriber. See this page for more details and to sign up today.
A Big-Mover event occurred but it didn't move the underlying stock by more than 20% up or down: Why? Keep in mind that it is not possible to predict with 100% accuracy, the magnitude of a stock move on the readout of a clinical trial event. And many times a stock may not move by at least 20% on a report-out of a Big Mover event because the data was not clearly positive or negative. This so-called mixed data situation can effect the magnitude and direction of a movement. For example, if there are 2 primary and 4 secondary endpoints, and a drug candidate passes some but not all of the endpoints, the stock movement will likely be different than if it passed or failed all of the endpoints. Last updated 8/30/23 (EJV clarified throught)
